Brochure – Cerba Research IHC Biomarkers

Cerba Research offers in-house in situ biomarkers expertise managed by our research scientists, with over 200 optimized IHC and IF protocols, from simplex to multiplex solutions, to suit the needs of any project. The scientific-driven R&D team can provide complete IHC assay development/optimization or assay transfer of clients’ methods and the subsequent fit-for-purpose validation.

Biomarkers can triple drug development success rates when used in clinical research. While scientific and technological advances have led to the discovery of more circulating biomarker candidates, the challenge lies in validating those biomarkers.

Cerba Research takes a personalized approach to biomarker assay development and validation to help clients improve their odds of success. This approach involves the experience of our leading scientists, and our five-continent laboratory network.

Our highly specialized custom assays, innovative anatomical pathology biomarker support, and biomarker strategies de-risk study conduct and generate the data you need to bring new therapies to light. From translational research to clinical through commercialization, Cerba actuates real-world data to help you reach patients and bring clarity to complex research.

Cerba Research provides flexible, tailored biomarker solutions through a network of labs across five continents. When you partner with us, you gain the operational and scientific expertise to advance targeted approaches and broad immune profiling. Together, we will develop biomarker strategies that help your trial succeed.

But which biomarkers can Cerba Research test on? Discover it here in this downloadable brochure.